Swiss-based biotechnology company Kuros Biosciences intends to raise funds through the rights offering of shares of its common stock to raise between Sfr20.15m ($20.68m) and Sfr25m ($25.66m).

The shares will be offered in the price range from Sfr12.5 ($12.83) to Sfr15.5 ($15.91) a share.

The company has concurrently announced a public offering of shares, proceeds from which are intended to be used for the commercialisation of the company’s products, MagnetOS and Neuroseal.

Austrian drug delivery company Suda has signed a binding memorandum of understanding (MoU) to acquire Aluztra Bio’s global intellectual property relating to Anagrelide, an anti-cancer agent that reduces the level of platelets and its potentially non-toxic analogues.

Aluztra Bio is a biotechnology company based in the UK.

"US-based biotechnology company ProLynx has partnered with Daiichi Sankyo, a Japanese pharmaceutical company."

US-based biotechnology company ProLynx has partnered with Daiichi Sankyo, a Japanese pharmaceutical company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership is intended at evaluating the company’s drug delivery linker technology in the eye.

US-based biopharmaceutical company Celsion Corporation intends to raise $5.5m in gross proceeds through the private placement of two million shares of its common stock or pre-funded warrants in lieu thereof.

Priced at $2.75 a share, the placement is expected to be subscribed to by institutional investors.

The proceeds are intended to be used for general corporate purposes.